ETV1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3486735	1.00	1/20
SCHEMBL19829781	1.00	1/20
SCHEMBL19829782	1.00	1/20
SCHEMBL29399443	1.00	1/20
SCHEMBL17669251	0.83	1/20
SCHEMBL17679820	0.83	1/20
SCHEMBL17679823	0.83	1/20
SCHEMBL29810794	0.83	1/20
SCHEMBL15337311	0.80	1/20
SCHEMBL15337268	0.78	1/20
SCHEMBL19419557	0.78	1/20
SCHEMBL13253318	0.77	1/20
SCHEMBL15337315	0.77	1/20
SCHEMBL15337353	0.77	1/20
SCHEMBL15337357	0.77	1/20
SCHEMBL19432898	0.77	1/20
SCHEMBL22199725	0.77	1/20
SCHEMBL3486433	0.75	1/20
SCHEMBL13253333	0.75	1/20
SCHEMBL15337274	0.75	1/20

Clinical trials — most relevant to ETV1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer	PHASE2	COMPLETED
First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)	PHASE2	COMPLETED
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis	PHASE2	ACTIVE_NOT_RECRUITING
Safety and Efficacy of Pucotenlimab in pLECC	PHASE2	RECRUITING
Pediatric Reporting of Adult-Onset Genomic Results	EARLY_PHASE1	COMPLETED
Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1	nan	COMPLETED
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma	nan	COMPLETED
Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.	nan	COMPLETED
Familial Investigations of Childhood Cancer Predisposition	nan	RECRUITING
MMP Polymorphisms and Acute Coronary Syndromes	nan	COMPLETED
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data	nan	COMPLETED
Does Preimplantation Genetic Diagnosis for Sex Selection Affect the Pregnancy and Miscarriage Rates in Women With an Expected Good Ovarian Response Undergoing IVF/ICSI Cycles?	nan	COMPLETED
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province	nan	COMPLETED
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features	nan	UNKNOWN
Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib	nan	RECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Map of Tumor Genetic Actionability in Argentina	nan	ACTIVE_NOT_RECRUITING
PREcision Diagnostics in Rare genetIC Diseases and Tumors - Long Read Sequencing	nan	RECRUITING
Genomic Analysis of Families With a History of Discordant Cancers	nan	RECRUITING
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics	nan	RECRUITING
Genetic Investigation of Solid Tumors Cohort	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping	nan	UNKNOWN
Research Study in Patients With Advanced Ovarian Epithelial Cancer	nan	WITHDRAWN
COsegregation of VARiants in Panel of Genes	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ETV1 binder may also engage these)

Protein	Name	Similarity
P41164	—	1.000	P41164 →
Q2KIC2	—	1.000	Q2KIC2 →
Q9CXC9	—	1.000	Q9CXC9 →
P41161	—	1.000	P41161 →
Q9PUQ1	—	0.999	Q9PUQ1 →
P28322	—	0.996	P28322 →
P43268	—	0.995	P43268 →
P01105	—	0.994	P01105 →
Q60430	—	0.993	Q60430 →
O09105	—	0.993	O09105 →
Q1KKW8	—	0.993	Q1KKW8 →
Q7Z353	—	0.993	Q7Z353 →
Q32NH9	—	0.993	Q32NH9 →
Q9HD90	—	0.993	Q9HD90 →
Q1KL10	—	0.991	Q1KL10 →
Q90837	—	0.991	Q90837 →
Q4R5G6	—	0.991	Q4R5G6 →
Q96NK8	—	0.991	Q96NK8 →
P81270	—	0.991	P81270 →
P48986	—	0.991	P48986 →
Q6EUW2	—	0.991	Q6EUW2 →
Q9I9D5	—	0.991	Q9I9D5 →
P79766	—	0.991	P79766 →
Q8R5I7	—	0.991	Q8R5I7 →
Q8CDG5	—	0.991	Q8CDG5 →
Q08DI0	—	0.991	Q08DI0 →
G3V7R4	—	0.990	G3V7R4 →
ERG	Transcriptional regulator ERG	0.990	landscape →
Q99697	—	0.990	Q99697 →
Q62661	—	0.990	Q62661 →